Drug
Anrikefon clinical trials
Also written HSK21542.
- studies test it
- 18
- open now
- 10
- in phase 3
- 3
- first study started
- 2020
Keep track of what changes. Save the anrikefon studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2026 (7)
| Year | Studies |
|---|---|
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 6
- Phase 3
- 3
- Phase 4
- 6
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 11
Haisco Pharmaceutical Group Co., Ltd. (5) · Sichuan Haisco Pharmaceutical Group Co., Ltd (2) · Peking University First Hospital (2) · Beijing Tsinghua Chang Gung Hospital (1) · Tianjin Medical University Cancer Institute and Hospital (1) · The First People's Hospital of Lianyungang (1) · Affiliated Hospital of Guangdong Medical University (1) · First Affiliated Hospital of Wenzhou Medical University (1)
Studies
Open first, then newest update. How each study uses anrikefon is read from its arms, and is right about nine times in ten.
Testing it · 18
- Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic SurgeryRecruitingPhase 4Peking University First HospitalNCT07525986Written as High-dose anrikefon
- A Randomized, Double-Blind, Placebo-Controlled Trial of Anrikefon for Postoperative Analgesia After Percutaneous NephrolithotomyNot yet recruitingPhase 4Beijing Tsinghua Chang Gung HospitalNCT07825142Written as Anrikefon
- Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Laparoscopic HepatectomyNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07826806Written as Anrikefon Injection
- Anrikefon Injection for Postoperative Analgesia in Thoracoscopic Lung Surgery: A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Single-Center Clinical StudyNot yet recruitingNot applicableThe First People's Hospital of LianyungangNCT07810413Written as Anrikefon Injection
- Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aPRecruitingPhase 4Zhujiang HospitalNCT07380113Written as Anrikefon
- A Study on the Efficacy and Safety of Anrikefon for Postoperative Pain Relief Following Laparoscopic CholecystectomyNot yet recruitingPhase 2Affiliated Hospital of Guangdong Medical UniversityNCT07741188Written as Anrikefon
- Safety and Efficacy of Anricfen for Postoperative Analgesia and Rehabilitation Promotion After Pancreaticoduodenectomy.Intervention Measures: For Normal Adults, Administer Ariceptin Injection Intravenously Post-operation at a Dose of 1 μg/Kgevery 8 Hours for Three Consecutive Days After Surgery.RecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07514637Written as Anrikefon
- Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic SurgeryRecruitingPhase 4Zhongshan Ophthalmic Center, Sun Yat-sen UniversityNCT07269106Written as Anrikefon
- Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and VomitingNot yet recruitingPhase 2First Affiliated Hospital of Wenzhou Medical UniversityNCT06593782Written as HSK21542
- An Economic Study of HSK21542 Injection for Prevention of Postoperative Nausea and VomitingRecruitingPhase 4Mengchang YangNCT06359535Written as HSK21542
- A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic SurgeryCompletedPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT07186426Written as HSK21542
- Anrikefon-based Patient-controlled Intravenous Analgesia After Laparoscopic SurgeryTerminatedPhase 4Peking University First HospitalNCT07246785Written as High-dose anrikefon
- A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients with Chronic Kidney Disease-Associated PruritusCompletedPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT05135390Written as HSK21542
- Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy VolunteersCompletedPhase 1Sichuan Haisco Pharmaceutical Group Co., LtdNCT04213196Written as HSK21542
- A Clinical Study to Evaluate Efficacy and Safety of HSK21542 for Postoperative Analgesia of Subjects Undergoing Elective Laparoscopic Surgery Under General AnesthesiaCompletedPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT04738357Written as HSK21542
- A Study Evaluating the Efficacy and Safety of HSK21542 Injection for Analgesia in Subjects Undergoing ColonoscopyCompletedPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT04470128Written as HSK21542 1 μg/kg
- A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With PruritusCompletedPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT04999787Written as HSK21542
- Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy VolunteersCompletedPhase 1Sichuan Haisco Pharmaceutical Group Co., LtdNCT04110886Written as HSK21542
Codes
What other systems call anrikefon · ClinicalTrials.gg INT014392
- UNII (FDA) 22SCY98BXVANRIKEFONOne source FDA
- NCI Thesaurus C190357AnrikefonOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 22SCY98BXV | ANRIKEFON | One source FDA |
| NCI Thesaurus | C190357 | Anrikefon | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.